Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost

Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered monthly during the ...